North Estonia Medical Centre: Difference between revisions
(→Trials) |
|||
| Line 61: | Line 61: | ||
== [[Learning Resources]] == | == [[Learning Resources]] == | ||
* '''[https://www.regionaalhaigla.ee/en/information-materials Information materials]''' | |||
* '''[https://www.regionaalhaigla.ee/en/application-and-issue-medical-records-and-radiological-examination-discs Issue of documents]''' | |||
* '''[https://www.regionaalhaigla.ee/en/processing-personal-data Processing of personal data]''' | |||
* '''[https://www.regionaalhaigla.ee/en/issuance-death-certificate Issuance of a death certificate]''' | |||
== [[Novel Therapies and Diagnostic Methods]] == | == [[Novel Therapies and Diagnostic Methods]] == | ||
== [[Cancer-related Patient Associations]] == | == [[Cancer-related Patient Associations]] == | ||
Revision as of 17:21, 4 November 2022
The North Estonia Medical Centre is one of the top healthcare providers in the country. The Medical Center’s statutes states their goal is "to provide high-quality, specialized medical care and ambulance services, to be the learning base of training that precedes and follows the acquiring of health care professionals’ qualifications and does healthcare-related study and research work."
Trials
Study of AGEN2034 in Advanced Tumors and Cervical Cancer
Summary: This is a 2-part trial: a Phase 1, open-label, dose-escalation study in subjects with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in subjects with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum-based treatment regimen.
Sponsor, manager, or home institution: Agenus Inc.
Intervention/Treatment: Drug: AGEN2034
Number of patients: 211 participants
Beginning Date: April 7, 2017
Last Update: November 3, 2022
Recruitment Status: Completed.
Cancer areas of interest: Advanced Cancer and Cervical Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Summary: This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.
Sponsor, manager, or home institution: Merck Sharp & Dohme LLC
Intervention/Treatment: Drug: Pembrolizumab; Radiation: Conventional Radiotherapy (Bladder only); Radiation: Conventional Radiotherapy (Bladder and pelvic nodes); Radiation: Hypofractionated Radiotherapy (Bladder only); Drug: Cisplatin; Drug: Fluorouracil (5-FU); Drug: Mitomycin C (MMC); Drug: Gemcitabine; Drug: Placebo to Pembrolizumab
Number of patients: 636 participants
Beginning Date: January 27, 2020
Last Update: October 21, 2022
Recruitment Status: Recruiting.
Cancer areas of interest: Urinary Bladder Neoplasms
